Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 13, 2014, 182 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.00 to $2,715,292,313,281.00.

Highlighted Stocks Traded by Insiders:

Wright Medical Group (WMGI) - FREE Research Report

Stookey Eric A, who is Pres., Extremities-Biologics at Wright Medical Group, sold 1,978 shares at $29.81 on May 13, 2014. Following this transaction, the Pres., Extremities-Biologics owned 81,554 shares meaning that the stake was reduced by 2.37% with the 1,978-share transaction.

Griffin William L. Jr, who is SVP GM BioMimetic Therapeutics at Wright Medical Group, sold 2,340 shares at $29.91 on May 13, 2014. Following this transaction, the SVP GM BioMimetic Therapeutics owned 68,886 shares meaning that the stake was reduced by 3.29% with the 2,340-share transaction.

Berry Lance A, who is Sr. VP & CFO at Wright Medical Group, sold 1,978 shares at $29.80 on May 13, 2014. Following this transaction, the Sr. VP & CFO owned 64,897 shares meaning that the stake was reduced by 2.96% with the 1,978-share transaction.

Walker Jennifer S., who is SVP - Process Improvement at Wright Medical Group, sold 700 shares at $29.91 on May 13, 2014. Following this transaction, the SVP - Process Improvement owned 35,510 shares meaning that the stake was reduced by 1.93% with the 700-share transaction.

The shares most recently traded at $29.68, down $0.23, or 0.77% since the insider transaction. Historical insider transactions for Wright Medical Group go as follows:

  • 4-Week # shares sold: 403
  • 12-Week # shares sold: 403
  • 24-Week # shares sold: 3.0 million

The average volume for Wright Medical Group has been 662,300 shares per day over the past 30 days. Wright Medical Group has a market cap of $1.5 billion and is part of the health care sector and health services industry. Shares are down 3.39% year-to-date as of the close of trading on Tuesday.

Wright Medical Group, Inc., a specialty orthopaedic company, provides extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients' lifestyles. Currently, there are 7 analysts who rate Wright Medical Group a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WMGI - FREE

TheStreet Quant Ratings rates Wright Medical Group as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Wright Medical Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MSC Industrial Direct (MSM) - FREE Research Report

Gershwind Erik, who is President and CEO at MSC Industrial Direct, sold 25,000 shares at $91.53 on May 13, 2014. Following this transaction, the President and CEO owned 33,813 shares meaning that the stake was reduced by 42.51% with the 25,000-share transaction.

The shares most recently traded at $90.92, down $0.61, or 0.67% since the insider transaction. Historical insider transactions for MSC Industrial Direct go as follows:

  • 4-Week # shares sold: 25,696
  • 12-Week # shares sold: 40,321
  • 24-Week # shares sold: 121,937

The average volume for MSC Industrial Direct has been 409,300 shares per day over the past 30 days. MSC Industrial Direct has a market cap of $4.5 billion and is part of the services sector and wholesale industry. Shares are up 12.37% year-to-date as of the close of trading on Tuesday.

MSC Industrial Direct Co., Inc., together with its subsidiaries, markets and distributes metalworking, and maintenance, repair, and operations (MRO) supplies primarily in the United States. The stock currently has a dividend yield of 1.43%. The company has a P/E ratio of 25.6. Currently, there are 6 analysts who rate MSC Industrial Direct a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MSM - FREE

TheStreet Quant Ratings rates MSC Industrial Direct as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full MSC Industrial Direct Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Biomarin Pharmaceutical (BMRN) - FREE Research Report

Ajer Jeffrey Robert, who is SVP, Chief Commercial Of at Biomarin Pharmaceutical, sold 621 shares at $57.96 on May 13, 2014. Following this transaction, the SVP, Chief Commercial Of owned 24,080 shares meaning that the stake was reduced by 2.51% with the 621-share transaction.

The shares most recently traded at $58.25, up $0.29, or 0.5% since the insider transaction. Historical insider transactions for Biomarin Pharmaceutical go as follows:

  • 4-Week # shares sold: 4,860
  • 12-Week # shares sold: 4,860
  • 24-Week # shares sold: 8,676

The average volume for Biomarin Pharmaceutical has been 1.8 million shares per day over the past 30 days. Biomarin Pharmaceutical has a market cap of $8.7 billion and is part of the health care sector and drugs industry. Shares are down 18.35% year-to-date as of the close of trading on Tuesday.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Currently, there are 10 analysts who rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BMRN - FREE

TheStreet Quant Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full Biomarin Pharmaceutical Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null